Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/26206144/ below:

Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial

Randomized Controlled Trial

Affiliations

• ¹ Wolfson Institute, Queen Mary University of London, London, UK. Electronic address: s.moss@qmul.ac.uk.
• ² Wolfson Institute, Queen Mary University of London, London, UK.
• ³ American Cancer Society, Atlanta, GA, USA.
• ⁴ University of Dundee, Dundee, UK.
• ⁵ Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

• PMID: 26206144
• DOI: 10.1016/S1470-2045(15)00128-X

Item in Clipboard

Randomized Controlled Trial

Sue M Moss et al. Lancet Oncol. 2015 Sep.

• ¹ Wolfson Institute, Queen Mary University of London, London, UK. Electronic address: s.moss@qmul.ac.uk.
• ² Wolfson Institute, Queen Mary University of London, London, UK.
• ³ American Cancer Society, Atlanta, GA, USA.
• ⁴ University of Dundee, Dundee, UK.
• ⁵ Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

• PMID: 26206144
• DOI: 10.1016/S1470-2045(15)00128-X

Item in Clipboard

• Correction to Lancet Oncol 2015; 16: 1127.

  [No authors listed] [No authors listed] Lancet Oncol. 2015 Sep;16(9):e427. doi: 10.1016/S1470-2045(15)00240-5. Lancet Oncol. 2015. PMID: 26370348 No abstract available.

Background: Age-specific effects of mammographic screening, and the timing of such effects, are a matter of debate. The results of the UK Age trial, which compared the effect of invitation to annual mammographic screening from age 40 years with commencement of screening at age 50 years on breast cancer mortality, have been reported at 10 years of follow-up and showed no significant difference in mortality between the trial groups. Here, we report the results of the UK Age trial after 17 years of follow-up.

Methods: Women aged 39-41 from 23 UK NHS Breast Screening Programme units years were randomly assigned by individual randomisation (1:2) to either an intervention group offered annual screening by mammography up to and including the calendar year of their 48th birthday or to a control group receiving usual medical care (invited for screening at age 50 years and every 3 years thereafter). Both groups were stratified by general practice. We compared breast cancer incidence and mortality by time since randomisation. Analyses included all women randomly assigned who could be traced with the National Health Service Central Register and who had not died or emigrated before entry. The primary outcome measures were mortality from breast cancer (defined as deaths with breast cancer coded as the underlying cause of death) and breast cancer incidence, including in-situ, invasive, and total incidence. Because there is an interest in the timing of the mortality effect, we analysed the results in different follow-up periods. This trial is registered, number ISRCTN24647151.

Findings: Between Oct 14, 1990, and Sept 25, 1997, 160 921 participants were randomly assigned; 53 883 women in the intervention group and 106 953 assigned to usual medical care were included in this analysis. After a median follow-up of 17 years (IQR 16·8-18·8), the rate ratio (RR) for breast cancer mortality was 0·88 (95% CI 0·74-1·04) from tumours diagnosed during the intervention phase. A significant reduction in breast cancer mortality was noted in the intervention group compared with the control group in the first 10 years after diagnosis (RR 0·75, 0·58-0·97) but not thereafter (RR 1·02, 0·80-1·30) from tumours diagnosed during the intervention phase. The overall breast cancer incidence during 17 year follow-up was similar between the intervention group and the control group (RR 0·98, 0·93-1·04).

Interpretation: Our results support an early reduction in mortality from breast cancer with annual mammography screening in women aged 40-49 years. Further data are needed to fully understand long-term effects. Cumulative incidence figures suggest at worst a small amount of overdiagnosis.

Funding: National Institute for Health Research Health Technology Assessment programme and the American Cancer Society. Past funding was received from the Medical Research Council, Cancer Research UK, the UK Department of Health, and the US National Cancer Institute.

Copyright © 2015 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

• Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.

  Duffy S, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith R, Evans A, Blyuss O, Johns L, Ellis I, Sasieni P, Wale C, Myles J, Moss S. Duffy S, et al. Health Technol Assess. 2020 Oct;24(55):1-24. doi: 10.3310/hta24550. Health Technol Assess. 2020. PMID: 33141657 Free PMC article. Clinical Trial.

• Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.

  Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA, Evans A, Blyuss O, Johns L, Ellis IO, Myles J, Sasieni PD, Moss SM. Duffy SW, et al. Lancet Oncol. 2020 Sep;21(9):1165-1172. doi: 10.1016/S1470-2045(20)30398-3. Epub 2020 Aug 12. Lancet Oncol. 2020. PMID: 32800099 Free PMC article. Clinical Trial.

• Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.

  Medical Advisory Secretariat. Medical Advisory Secretariat. Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1. Ont Health Technol Assess Ser. 2007. PMID: 23074501 Free PMC article.

• Screening for breast cancer with mammography.

  Gøtzsche PC, Jørgensen KJ. Gøtzsche PC, et al. Cochrane Database Syst Rev. 2013 Jun 4;2013(6):CD001877. doi: 10.1002/14651858.CD001877.pub5. Cochrane Database Syst Rev. 2013. PMID: 23737396 Free PMC article. Review.

• Long-term effects of mammography screening: updated overview of the Swedish randomised trials.

  Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Nyström L, et al. Lancet. 2002 Mar 16;359(9310):909-19. doi: 10.1016/S0140-6736(02)08020-0. Lancet. 2002. PMID: 11918907 Review.

• History of Mammography: Analysis of Breast Imaging Diagnostic Achievements over the Last Century.

  Nicosia L, Gnocchi G, Gorini I, Venturini M, Fontana F, Pesapane F, Abiuso I, Bozzini AC, Pizzamiglio M, Latronico A, Abbate F, Meneghetti L, Battaglia O, Pellegrino G, Cassano E. Nicosia L, et al. Healthcare (Basel). 2023 May 30;11(11):1596. doi: 10.3390/healthcare11111596. Healthcare (Basel). 2023. PMID: 37297735 Free PMC article. Review.

• Digital Breast Tomosynthesis: Update on Technology, Evidence, and Clinical Practice.

  Gao Y, Moy L, Heller SL. Gao Y, et al. Radiographics. 2021 Mar-Apr;41(2):321-337. doi: 10.1148/rg.2021200101. Epub 2021 Feb 5. Radiographics. 2021. PMID: 33544665 Free PMC article.

• Should we expect all-cause mortality reductions in large screening studies?

  Dobbin KK, Ebell M. Dobbin KK, et al. Br J Gen Pract. 2018 Jun;68(671):290-291. doi: 10.3399/bjgp18X696545. Br J Gen Pract. 2018. PMID: 29853594 Free PMC article. No abstract available.

• Unexpected breast cancer mimicking benign lesions on ultrasound-guided vacuum-assisted excision biopsy: A retrospective cross-sectional study over a 20-year period.

  Zhou W, Luo H, Zhao H, Peng Y. Zhou W, et al. Front Oncol. 2023 Feb 1;13:1108689. doi: 10.3389/fonc.2023.1108689. eCollection 2023. Front Oncol. 2023. PMID: 36816915 Free PMC article.

• Adults with Cerebral Palsy: Navigating the Complexities of Aging.

  Kumar DS, Perez G, Friel KM. Kumar DS, et al. Brain Sci. 2023 Sep 8;13(9):1296. doi: 10.3390/brainsci13091296. Brain Sci. 2023. PMID: 37759897 Free PMC article. Review.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3